US Bancorp’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

US Bancorp’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200	Closed	-$11K	–	3995
2021 Q1	$11K	Hold	200	–	–	﹤0.01%	3239
2020 Q4	$14K	Hold	200	–	–	﹤0.01%	3044
2020 Q3	$51K	Buy	200 +33	+20%	+$6.76K	﹤0.01%	2384
2020 Q2	$28K	Hold	167	–	–	﹤0.01%	2660
2020 Q1	$12K	Buy	167 +149	+828%	+$11.6K	﹤0.01%	2957
2019 Q4	$1K	Hold	18	–	–	﹤0.01%	3548
2019 Q3	$1K	Hold	18	–	–	﹤0.01%	3475
2019 Q2	$1K	Hold	18	–	–	﹤0.01%	3533
2019 Q1	$1K	Hold	18	–	–	﹤0.01%	3479
2018 Q4	$1K	Hold	18	–	–	﹤0.01%	3480
2018 Q3	$1K	Hold	18	–	–	﹤0.01%	3545
2018 Q2	$1K	Hold	18	–	–	﹤0.01%	3537
2018 Q1	$1K	Hold	18	–	–	﹤0.01%	3531
2017 Q4	$1K	Hold	18	–	–	﹤0.01%	3517
2017 Q3	$1K	Hold	18	–	–	﹤0.01%	3474
2017 Q2	$1K	Hold	18	–	–	﹤0.01%	3444
2017 Q1	$1K	Hold	18	–	–	﹤0.01%	3449
2016 Q4	$1K	Hold	18	–	–	﹤0.01%	3433
2016 Q3	$1K	Hold	18	–	–	﹤0.01%	3428
2016 Q2	$1K	Hold	18	–	–	﹤0.01%	3458
2016 Q1	$1K	Hold	18	–	–	﹤0.01%	3427
2015 Q4	$1K	Hold	18	–	–	﹤0.01%	3503
2015 Q3	$1K	Hold	18	–	–	﹤0.01%	3482
2015 Q2	$1K	Hold	18	–	–	﹤0.01%	3473
2015 Q1	$1K	Hold	18	–	–	﹤0.01%	3481
2014 Q4	$1K	Buy	+18	New	+$946	﹤0.01%	3456

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

US Bancorp's BCLI Position: Q2 2021 in Review

US Bancorp sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 200 shares — an estimated $11K sold.

US Bancorp first reported a position in BCLI in Q4 2014 and held it in 26 quarters. The position peaked at $51K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

US Bancorp reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
US Bancorp sold 200 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $11K.
US Bancorp first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 26 quarters.
US Bancorp's BRAINSTORM CELL THERAPUTC position peaked at $51K in Q3 2020.
57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on US Bancorp's 13F filing for Q2 2021, filed 5 Aug 2021.